Platinum Investment Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Platinum Investment Management’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-134,989	Closed	-$1.55M	–	148
2022 Q4	$1.55M	Sell	134,989 -86,710	-39%	-$1.08M	0.06%	89
2022 Q3	$2.79M	Hold	221,699	–	–	0.12%	62
2022 Q2	$2.35M	Hold	221,699	–	–	0.09%	76
2022 Q1	$3.6M	Hold	221,699	–	–	0.11%	65
2021 Q4	$3.07M	Buy	221,699 +92,011	+71%	+$1.22M	0.09%	80
2021 Q3	$1.86M	Sell	129,688 -39,027	-23%	-$615K	0.05%	103
2021 Q2	$2.67M	Hold	168,715	–	–	0.06%	85
2021 Q1	$1.72M	Sell	168,715 -289,360	-63%	-$2.98M	0.04%	96
2020 Q4	$3.41M	Sell	458,075 -4,327	-0.9%	-$22.3K	0.08%	65
2020 Q3	$1.59M	Hold	462,402	–	–	0.04%	88
2020 Q2	$2.2M	Sell	462,402 -308,984	-40%	-$1.23M	0.05%	80
2020 Q1	$1.54M	Buy	+771,386	New	+$2.12M	0.04%	80

Other funds holding BCRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Platinum Investment Management's BCRX Position: Q1 2023 in Review

Platinum Investment Management sold out of BioCryst Pharmaceuticals (BCRX) in Q1 2023, closing a stake of 134,989 shares — an estimated $1.55M sold.

Platinum Investment Management first reported a position in BCRX in Q1 2020 and held it in 12 quarters. The position peaked at $3.6M in Q1 2022. 241 funds tracked by Wall St. Rank hold BCRX as of Q1 2023.

Platinum Investment Management reported no remaining BioCryst Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Platinum Investment Management sold 134,989 BioCryst Pharmaceuticals shares in Q1 2023, an estimated $1.55M.
Platinum Investment Management first reported a position in BioCryst Pharmaceuticals in Q1 2020 and held it in 12 quarters.
Platinum Investment Management's BioCryst Pharmaceuticals position peaked at $3.6M in Q1 2022.
241 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2023.

Based on Platinum Investment Management's 13F filing for Q1 2023, filed 12 May 2023.